Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

566 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Gross cystic disease fluid protein 15 (GCDFP-15) expression in breast cancer subtypes.
Darb-Esfahani S, von Minckwitz G, Denkert C, Ataseven B, Högel B, Mehta K, Kaltenecker G, Rüdiger T, Pfitzner B, Kittel K, Fiedler B, Baumann K, Moll R, Dietel M, Eidtmann H, Thomssen C, Loibl S. Darb-Esfahani S, et al. Among authors: dietel m. BMC Cancer. 2014 Jul 28;14:546. doi: 10.1186/1471-2407-14-546. BMC Cancer. 2014. PMID: 25070172 Free PMC article. Clinical Trial.
Identification of biology-based breast cancer types with distinct predictive and prognostic features: role of steroid hormone and HER2 receptor expression in patients treated with neoadjuvant anthracycline/taxane-based chemotherapy.
Darb-Esfahani S, Loibl S, Müller BM, Roller M, Denkert C, Komor M, Schlüns K, Blohmer JU, Budczies J, Gerber B, Noske A, du Bois A, Weichert W, Jackisch C, Dietel M, Richter K, Kaufmann M, von Minckwitz G. Darb-Esfahani S, et al. Among authors: dietel m. Breast Cancer Res. 2009;11(5):R69. doi: 10.1186/bcr2363. Breast Cancer Res. 2009. PMID: 19758440 Free PMC article. Clinical Trial.
Thymosin beta 15A (TMSB15A) is a predictor of chemotherapy response in triple-negative breast cancer.
Darb-Esfahani S, Kronenwett R, von Minckwitz G, Denkert C, Gehrmann M, Rody A, Budczies J, Brase JC, Mehta MK, Bojar H, Ataseven B, Karn T, Weiss E, Zahm DM, Khandan F, Dietel M, Loibl S. Darb-Esfahani S, et al. Among authors: dietel m. Br J Cancer. 2012 Nov 20;107(11):1892-900. doi: 10.1038/bjc.2012.475. Epub 2012 Oct 18. Br J Cancer. 2012. PMID: 23079573 Free PMC article.
Evaluation of Mucin-1 protein and mRNA expression as prognostic and predictive markers after neoadjuvant chemotherapy for breast cancer.
Sinn BV, von Minckwitz G, Denkert C, Eidtmann H, Darb-Esfahani S, Tesch H, Kronenwett R, Hoffmann G, Belau A, Thommsen C, Holzhausen HJ, Grasshoff ST, Baumann K, Mehta K, Dietel M, Loibl S. Sinn BV, et al. Among authors: dietel m. Ann Oncol. 2013 Sep;24(9):2316-24. doi: 10.1093/annonc/mdt162. Epub 2013 May 9. Ann Oncol. 2013. PMID: 23661292 Free article. Clinical Trial.
CD24 expression is a new prognostic marker in breast cancer.
Kristiansen G, Winzer KJ, Mayordomo E, Bellach J, Schlüns K, Denkert C, Dahl E, Pilarsky C, Altevogt P, Guski H, Dietel M. Kristiansen G, et al. Among authors: dietel m. Clin Cancer Res. 2003 Oct 15;9(13):4906-13. Clin Cancer Res. 2003. PMID: 14581365
Prognostic relevance of AGR2 expression in breast cancer.
Fritzsche FR, Dahl E, Pahl S, Burkhardt M, Luo J, Mayordomo E, Gansukh T, Dankof A, Knuechel R, Denkert C, Winzer KJ, Dietel M, Kristiansen G. Fritzsche FR, et al. Among authors: dietel m. Clin Cancer Res. 2006 Mar 15;12(6):1728-34. doi: 10.1158/1078-0432.CCR-05-2057. Clin Cancer Res. 2006. PMID: 16551856 Free article.
Phospho-mTOR and phospho-4EBP1 in endometrial adenocarcinoma: association with stage and grade in vivo and link with response to rapamycin treatment in vitro.
Darb-Esfahani S, Faggad A, Noske A, Weichert W, Buckendahl AC, Müller B, Budczies J, Röske A, Dietel M, Denkert C. Darb-Esfahani S, et al. Among authors: dietel m. J Cancer Res Clin Oncol. 2009 Jul;135(7):933-41. doi: 10.1007/s00432-008-0529-5. Epub 2008 Dec 24. J Cancer Res Clin Oncol. 2009. PMID: 19107520
566 results